Cellis is developing Macrophage Drug Conjugates (MDCs) which is a breakthrough, new class of therapy for solid tumors. Cellis uses allogeneic macrophages conjugated with therapeutic medications for treatment of several solid tumors. Our focus is on glioblastoma, ovarian and pancreatic cancer.

Location

Canton

Facts & figures

  • Type of organization
    Private company
  • Year of foundation
    2018
  • Number of employees in Switzerland
    1-9

Key business

Core competencies

Keep browsing

You may also be interested in